WIRB-Copernicus Group Revenue and Competitors
Estimated Revenue & Valuation
- WIRB-Copernicus Group's estimated annual revenue is currently $267.3M per year.
- WIRB-Copernicus Group's estimated revenue per employee is $201,000
Employee Data
- WIRB-Copernicus Group has 1330 Employees.
- WIRB-Copernicus Group grew their employee count by 6% last year.
WIRB-Copernicus Group's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CMO | Reveal Email/Phone |
3 | Chief Commercial Officer, Ethical Review Division | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | VP, Chief Information Security Officer | Reveal Email/Phone |
6 | Chief Change Officer | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Chief Information Officer | Reveal Email/Phone |
9 | Chief Technology Officer | Reveal Email/Phone |
10 | Chief Commercial Officer | Reveal Email/Phone |
WIRB-Copernicus Group Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is WIRB-Copernicus Group?
WCG is the world's largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG's solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials. WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life. For more information, please visit www.wcgclinical.com.
keywords:Biotechnology,Healthcare,PharmaceuticalsN/A
Total Funding
1330
Number of Employees
$267.3M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
WIRB-Copernicus Group News
WIRB Copernicus Group. Find additional highlights on the growth strategies adopted by vendors and their product offerings. Read Free Sample...
WCG Total Safety provides turnkey management of drug safety, pharmacovigilance, and safety reporting technology to meet demanding regulatory...
PRINCETON, N.J., July 26, 2021 /PRNewswire/ -- WCG today announced the acquisition of VeraSci, a global provider of specialty scientific expertise and eClinical software to support the design and execution of clinical trials focused on central nervous system (CNS) disorders. The addition of Ve ...
PRINCETON, N.J., Dec. 3, 2020 /PRNewswire/ -- WCG today announced its acquisition of Trifecta Clinical, a proven leader in technology-enabled clinical trial solutions, including its comprehensive site communication platform InvestigatorSpace®, virtual training programs and safety documentation ...
PRINCETON, N.J., Aug. 27, 2019 /PRNewswire/ -- The WIRB-Copernicus Group®'s (WCG™) Clinical Services Division introduces Velos ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $420.7M | 1366 | 8% | N/A |
#2 | $302.3M | 1489 | N/A | N/A |
#3 | $275.4M | 1554 | 7% | N/A |
#4 | $336.1M | 1715 | N/A | N/A |
#5 | $350.4M | 1726 | 24% | N/A |
WIRB-Copernicus Group Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2017-05-10 | $ | 3043295 | Article | |
2018-07-26 | $ | 2604337 | Article |